<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26679">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816815</url>
  </required_header>
  <id_info>
    <org_study_id>14723</org_study_id>
    <secondary_id>2011-001760-22</secondary_id>
    <nct_id>NCT01816815</nct_id>
  </id_info>
  <brief_title>Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of BAY1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian
      function; return of menstrual bleeding after treatment; safety and tolerability; PK/PD
      (pharmacokinetic/pharmacodynamic) relationship
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Non-bleeding rate (i.e. women without bleeding from treatment day 9 until the end of treatment)</measure>
    <time_frame>After three months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return of menstrual bleeding after treatment</measure>
    <time_frame>Up to two months after last treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>BAY1002670 [0.1mg]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1002670 [0.5mg]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1002670 [1.0mg]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1002670 [2.0mg]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1002670 [5.0mg]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1002670</intervention_name>
    <arm_group_label>BAY1002670 [0.1mg]</arm_group_label>
    <arm_group_label>BAY1002670 [0.5mg]</arm_group_label>
    <arm_group_label>BAY1002670 [1.0mg]</arm_group_label>
    <arm_group_label>BAY1002670 [2.0mg]</arm_group_label>
    <arm_group_label>BAY1002670 [5.0mg]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects

          -  Sterilized by tubal ligation

          -  Age 18-45 years

          -  Body mass index (BMI) at screening: ≥ 18 and ≤ 32 kg/m²

          -  At least 3 consecutive regular menstrual cycles with a cycle length of 24 - 35 days
             before first screening examination according to the subject's history

          -  Absence of clinically relevant abnormal findings in the pre-treatment endometrial
             biopsy

        Exclusion Criteria:

          -  Regular use of medicines (incl. anabolics)

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination and effects of the study drugs will
             not be normal

          -  Amenorrhea for more than 3 months within the last 6 months before the first screening
             examination

          -  Lacking suitability for frequent transvaginal ultrasonography (TVU) examinations

          -  Clinically relevant findings (e.g. blood pressure, electrocardiogram [ECG], physical
             and gynecological examination, laboratory examination)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <zip>BT2 7BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://healthcare.bayer.com/scripts/pages/en/research_development/clinical_trials/trial_finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK/PD</keyword>
  <keyword>BAY1002670</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
